ICYMI: More Steps Required for Experimental ADPKD Drug in Order to Obtain Orphan Designation
TeroVesalainen / Pixabay

ICYMI: More Steps Required for Experimental ADPKD Drug in Order to Obtain Orphan Designation

According to a story from thenewsreports.com, the biopharmaceutical company XORTX Therapeutics, Inc., recently announced that the company and its partner Cato Clinical Research have received correspondence from the US Food…

Continue Reading ICYMI: More Steps Required for Experimental ADPKD Drug in Order to Obtain Orphan Designation

Drug for Treating Autosomal Dominant Polycystic Kidney Disease Gets Expanded Indication

According to a story from businesswire.com, Otsuka Pharmaceutical Europe Ltd recently announced that its product JINARC, also known as tolvaptan, now has an expanded therapeutic indication after a recent approval…

Continue Reading Drug for Treating Autosomal Dominant Polycystic Kidney Disease Gets Expanded Indication

A Long Term Study of a Treatment for Autosomal Dominant Polycystic Kidney Disease Has Finished

According to a story from Medical Xpress, a long term study testing a treatment for autosomal dominant polycystic kidney disease (ADPKD) has recently concluded. The treatment in question is a…

Continue Reading A Long Term Study of a Treatment for Autosomal Dominant Polycystic Kidney Disease Has Finished